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Abstract
Introduction
The aim of this international collaborative effort was to report 36-month longitudinal changes
using the 6MWT in ambulant patients affected by Duchenne muscular dystrophy amenable
to skip exons 44, 45, 51 or 53.
Materials and methods
Of the 92 patients included in the study, 24 had deletions amenable to skip exon 44, 27 exon
45, 18 exon 51, and 28 exon 53. Five patients with a single deletion of exon 52 were counted
in both subgroups skipping exon 51 and 53.
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Results
The difference between subgroups amenable to skip different exons was not significant at
12 months but became significant at both 24 (p�0.05) and 36 months (p�0.01).
Discussion
Mutations amenable to skip exon 53 had lower baseline values and more negative changes
than the other subgroups while those amenable to skip exon 44 had better results both at
baseline and at follow up. Deletions amenable to skip exon 45 were associated with a more
variable pattern of progression. Single exon deletions were more often associated with less
drastic changes but this was not always true in individual cases.
Conclusion
Our results confirm that the progression of disease can differ between patients with different
deletions, although the changes only become significant from 24 months onwards. This
information is relevant because there are current clinical trials specifically targeting patients
with these subgroups of mutations.
Introduction
The introduction of glucocorticoid therapy and the implementation of standards of care have,
in the last decades, dramatically changed survival and natural history of patients affected by
Duchenne muscular dystrophy (DMD)[1, 2]. More recently, there has been increasing evi-
dence that an additional benefit may come from new therapeutically approaches based on
genetic mechanisms targeting specific types of mutation [3, 4]. Recent clinical trials using dys-
trophin restoration approaches, such as antisense oligonucleotides for exons skipping or
approaches targeting non-sense mutations have shown encouraging results. The results appear
to be more obvious after the first year of treatment [3]. The interpretation of the long-term
results of the clinical trials however is complicated by the paucity of long-term prospective nat-
ural history data in patients with distinct genotypes.
Retrospective data on loss of ambulation and other features of disease progression [5, 6] in
patients with deletions amenable to skip exon 44, 45, 51 and 53 have recently become available,
but only few have reported prospectively collected longitudinal data in these subgroups of
patients[7–9]. These papers suggest that the changes in the individual subgroups do not appear
to be significantly different from the mean changes observed in the whole cohort of DMD
patients over a year [7], but the difference becomes more obvious on a longer follow up (24
months), especially when individual subgroups were compared to each other [8].
As there are a number of ongoing or planned studies targeting deletions amenable to skip
exon 44, 45, 51 and 53 (NCT03218995, NCT03375255, NCT02500381, NCT02310906,
NCT03508947, NCT02081625), it has become important to obtain more detailed information
on the patterns of progression related to these different genotypes.
The aim of our collaborative effort was to obtain longitudinal prospective changes over 36
months in the six minutes walking test (6MWT) in a large cohort of DMD ambulant patients
amenable to skip exons 44, 45, 51 and 53.
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Materials and methods
The study is part of a longitudinal multi-centric cohort study involving 12 tertiary neuromus-
cular centers in Italy, 1 center in Belgium and one in the United Kingdom. Patients were
recruited between January 2008 and March 2015 and followed for at least three years. Inclu-
sion criteria at baseline were: genetically confirmed DMD diagnosis, patient still ambulant and
able to walk independently for at least 150 meters, no severe or moderate intellectual disability
or behavioral problems. In this paper, we only included patients with deletions amenable to
skip exons 44, 45, 51 and 53. The study was approved by the Ethical Committee of each center
(Catholic University, Rome, Ospedale Bambino Gesu`, Rome; Istituto Mondino, Pavia; Gaslini
Institute, Genova; Besta Institute, Milan; Stella Maris Institute, Pisa; University of Napoli, Uni-
versity of Messina; University of Torino; University of Padova; University of Milano; Centro
Clinico Nemo Milano, University Hospitals Leuven, NHS Multicentric Research Ethics Com-
mittee, England). Parents of participants (all our patients were minor/children) and patients
were informed that the data collected as part of our routine clinical assessment were going to
be used anonymously for an observational study defining natural history of the diseases and
they all gave written consent. Type and regime of steroids were also noted.
6MWT
All ambulant DMD boys performed 6MWT according to the ATS guidelines modified by hav-
ing two examiners, one recording time and distances and one staying close to the patient for
safety issues [10, 11]. As part of the routine assessments in all centers, patients are seen at least
once every 12 months. Data were collected from the first assessment after recruitment (base-
line) and at 12, 24, 36-months after baseline. Details of the training for the physiotherapists
involved in the study and of the inter-observer reliability for 6MWT among the centers have
already been reported [12, 13].
Time to rise from the floor (TRF)
As part of this study all boys performed at each visit the timed items including time to rise
from the floor (TRF). The TRF was performed recording the time taken to complete the task.
It measures the time taken to rise from supine to standing[14]. The number of DMD boys
unable to perform the task at each time point was noted. The boys who were able to perform
the task were subdivided into two groups, based on the ability to perform the task in less or
more than 6 seconds. Data were collected from the first assessment after recruitment (baseline)
and from the 12, 24, 36-month assessments.
Statistical analysis
The 6MWT was evaluated longitudinally at 12, 24 and 36 months. Descriptive statistics (N,
mean, SD, range) were used.
Analysis of variance model (ANOVA) was used to assess heterogeneity among groups of
the six minutes walking distance (6MWD) at baseline and at 12, 24, 36-month assessments.
The test was performed according to the type of skipping exons 44, 45, 51, 53 and the use of
steroids at baseline (naive vs alternate or continuous).
Non-parametric Wilcoxon signed-rank test was used in the whole study group to compare
differences in 12, 24, 36 months assessment adjusting for baseline 6MWT value (<350 mt vs
�350 mt) and TRF (< or > 6 sec). P value was set at< 0.05.
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Results
Of the 354 DMD patients included in the overall DMD longitudinal study, 228 had deletions,
with 131 having deletions amenable to skip exons 44, 45, 51 and 53.
Of these 131 DMD patients, 92 (mean age 7.86 years (SD±2.32) fulfilled the inclusion crite-
ria and entered the study. The remaining 39 could not be recruited because lost at follow up
(n = 8), or participating in clinical trials (n = 22) or because they had been followed for less
than three years or had incomplete data (n = 9).
Twenty-four of the 92 had deletions amenable to skip for exon 44, 27 amenable to skip for
exon 45, 18 had deletions amenable to skip for 51, and 28 had deletions amenable to skip exon
53. Five patients with a single deletion of exon 52 were counted in both subgroups skipping
exon 51 and 53. Of the 92 boys, 35 were under 7 years of age at the time of the first assessment
(12 not on steroids, 8 on alternate and 15 on continuous steroids), 57 were above 7 years (4
not on steroids, 34 on alternate and 19 on continuous steroids). None of the patients discon-
tinued steroid treatment during the study.
6MWT
Table 1 reports details of the 6MWT in the whole group with deletions and in our study cohort
with 92 patients amenable to skip exons 44, 45, 51 and 53. Twenty-one patients lost ambula-
tion within 36 months from baseline. When the boys lost the ability to perform the 6MWT
they were scored as 0 meters. The mean age at baseline of the boys who lost ambulation was
9.15 years (SD±1.71). Thirty-five of the 92 patients were younger than 7 years of age, 57 were 7
year or older. On the 6MWT a difference was found between the two groups under and above
7 years of age at 24 month (p =<0.05) and at 36-month assessment (p =< 0.05).
Thirty-four of the 92 patients had 6MWD < 350 mt, 58 had 6MWD� 350 mt at baseline.
When we analyzed the 6MWT mean changes from baseline a difference was found between
the two groups below and above 350 mt at 12 months (p�0.001), 24 months (p�0.001) and at
36 months (p�0.001).
No difference on the 6MWT mean values was found among the different steroids groups
(no steroids vs alternate vs continuous regime) at baseline, 12, 24 and 36 months.
TRF
Fifty-six of the 92 patients had TRF below 6 sec and 31 had TRF above or equal to 6 seconds at
baseline. No data were available from 5 patients (1 amenable to skip for exon 51, 2 exon 44 and
2 exons 45). Table 2 reports details of the TRF in the study cohort according to mutations ame-
nable to skip exons 44, 45, 51 and 53.
Table 1. Details of the 6MWT in the whole group and in the study cohort.
Group N Age at baseline,
mean (SD)
6MWT at baseline,
mean (SD)
Age at 24 months,
mean (SD)
6MWT at 24
months, mean (SD)
Age at 36 months,
mean (SD)
6MWT at 36
months, mean (SD)
All deletions 169 7.77 (±2.50) 375.51 (±77.76) 9.50
(±2.58)
341.28 (±146.96) 10.49
(±2.58)
293.21 (±183.31)
All deletions amenable to
skip 44, 45, 51 and 53
92 7.86
(±2.32)
381.13 (±83.64) 9.55
(±2.39)
337.65 (±156.70) 10.53
(±2.41)
285.50 (±189.42)
Amenable to exon skipping
<7 years
35 5.38 (±0.84) 379.68 (±56.39) 7.35
(±0.86)
441.80 (±71.96) 8.30
(±0.92)
388.01 (±125.55)
Amenable to exon skipping
�7 years
57 9.39 (±1.45) 382.03 (±97.13) 11.39
(±1.52)
321.94 (±156.29) 12.40
(±1.51)
222.56 (±195.29)
https://doi.org/10.1371/journal.pone.0218683.t001
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On the 6MWT a difference was found between the groups below and above 6 seconds on
the TRF at baseline (p�0.0001), 12 months (p�0.0001), 24 months (p�0.0001) at 36 months
(p�0.0001).
Skip 44
Twenty-four patients were amenable to skip exon 44. The mean 6MWT was of 402.25 mt at
baseline. Mean changes from baseline were of +3.85 mt at 12 month +9.75 mt at 24 months
and– 43.04 mt at 36 months. Twelve were younger than 7 years of age and 12 were above 7
years. (Table 3; Figs 1 and 2) Two lost ambulation at 36 months from baseline, their mean age
at baseline was 10.5 years (SD ±0.71).
Skip 45
Twenty-seven patients were amenable to skip exon 45. The mean 6MWT was of 377.27 mt at
baseline. Mean changes from baseline were of -27.28 mt at 12 month, -39.79 mt at 24 months
and -50.85 mt at 36 months. Eleven were younger than 7 years of age and 16 were above 7
years. (Table 3; Figs 1 and 2). Five lost ambulation at 36 months from baseline, their mean age
at baseline was 9.59 years (SD ±0.86).
Skip 51
Eighteen patients were amenable to skip exon 51. The mean 6MWT was of 400.46 mt at base-
line. Mean changes from baseline were of -46.90 mt at 12 months. -86.73 mt at 24 months and
Table 2. Baseline 12, 24, 36 months TRF according to mutations amenable to skip exons 44, 45, 51 and 53.
Age TRF (mean) Unable to perform TRF (n)
Subgroups by skipping Baseline 12
months
24
months
36
months
12
months
24
months
36
months
Study cohort
(n:92)
44 (n:22) 4,49 5,73 6,02 8,68 1 2 3
45 (n:25) 5,72 5,60 5,99 5,78 2 4 6
51 (n:17) 7,36 5,46 7,41 5,32 3 5 7
53 (n:28) 6,21 9,62 11,25 9,90 3 8 13
https://doi.org/10.1371/journal.pone.0218683.t002
Table 3. Baseline 12, 24, 36 month 6MWT values (range, mean and median) subdivided according to genotype and age.
AGE 6MWT
Subgroups by
skipping
MIN MEAN MEDIAN MAX Baseline 12
months
24
months
36
months
12 month
changes
24 month
changes
36 month
changes
Study cohort
(n:97)
44 (n:24) 3.32 7.48 7.23 14.30 402.25 406.09 412.00 359.21 3.85 9.75 -43.04
45 (n:27) 4.36 7.86 8.01 12.12 377.27 349.99 337.48 326.42 -27.28 -39.79 -50.85
51 (n:18) 4.00 8.38 8.80 11.53 400.46 353.56 313.72 253.11 -46.90 -86.73 -147.34
53 (n:28) 4.12 8.14 8.55 11.60 359.46 330.49 294.31 190.93 -28.97 -65.15 -168.54
<7 years
(n:33)
44 (n:12) 3.32 5.45 5.78 6.90 388.66 411.28 446.82 420.67 22.62 58.16 32.01
45 (n:9) 4.36 5.56 5.55 6.83 384.13 390.05 416.30 442.13 5.92 32.18 58.00
51 (n:3) 4.00 4.56 4.08 5.60 386.83 415.67 441.67 437.33 28.83 54.83 50.50
53 (n:9) 4.12 5.33 5.20 6.07 359.89 373.01 353.56 261.89 13.12 -6.33 -98.00
� 7 years
(n:64)
44 (n:12) 7.57 9.52 9.10 14.30 415.83 401.33 377.18 297.75 -14.50 -38.65 -118.08
45 (n:18) 7.00 9.45 9.33 12.12 372.56 327.46 279.68 246.88 -45.09 -92.88 -125.68
51 (n:15) 7.00 9.15 9.14 11.53 403.18 341.13 288.13 216.27 -62.05 -115 -187
53 (n:19) 7.00 9.47 9.76 11.60 359.26 310.35 264.69 157.32 -48.91 -95 -202
https://doi.org/10.1371/journal.pone.0218683.t003
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-147.34 mt at 36 months. Three were younger than 7 years of age and 15 were above 7 years
(Table 3; Figs 1 and 2). Six lost ambulation at 36 months from baseline, their mean age at base-
line was 9.23 years (SD ±1.66).
Skip 53
Twenty-eight patients were amenable to skip exon 53. The mean 6MWT was of 359.46 mt at
baseline. Mean changes from baseline were of -28.97 mt at 12 months, -65.15 mt at 24 months
and -168.54 mt at 36 months.
Nine were younger than 7 years of age and 19 were above 7 years (Table 3; Figs 1 and 2).
Nine lost ambulation at 36 months from baseline, their mean age at baseline was 8.53 years
(SD ±2.18).
When we analyzed the 6MWT mean changes from baseline, there was a significant differ-
ence between deletions amenable to skip exons 44, 45, 51 or 53 at 24 (p�0.05) and 36-months
(p�0.01) but not at 12 months (p = 0.17).
Table 3 reports details of the 6MWT in the study cohort according to mutations amenable
to skip exons 44, 45, 51 and 53.
Figs 1 and 2 shows details of the mean changes in the whole study cohort and in the individ-
ual subgroups skipping exons 44, 45, 51 and 53.
Discussion
The need for long term natural history studies reporting the progression of different genotypes
over a long period of time has recently been highlighted by the recent Eteplirsen study
Fig 1. Mean 6MWT changes in the whole study cohort and in individual subgroups skipping exons 44, 45, 51 and
53 according to age. Panel A: Study Cohort. Panel B:<7 years of age. Panel C:�7 years of age.
https://doi.org/10.1371/journal.pone.0218683.g001
Fig 2. Individual 6MWT changes with details of the mutations within skipping subgroups. Panel A: Cohort
skipping exon 44. Panel B: Cohort skipping exon 45. Panel C: Cohort skipping exon 51. Panel D: Cohort skipping exon
53.✳ = TRF� 6 sec, � = TRF not performed.
https://doi.org/10.1371/journal.pone.0218683.g002
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targeting mutations amenable to skip exon 51 [3]. The study clearly shows that the benefit of
treatment is better seen after the first year and becomes more evident with increasing time.
These results indicate the need of longer studies to establish the efficacy of drugs with similar
mechanism of action. A recent workshop on clinical trial design involving various stakeholders
including patients and advocacy groups has however highlighted that patients and their fami-
lies would not be prepared to enter a study if the duration of the placebo treatment is longer
than 12 or 18 months, proposing that natural history data could be used as external controls
for longer studies[15].
One of the concerns with using previous natural history studies with patients classified
according to their genotype is that the numbers in each subgroup, even in large networks, are
relatively small and often include heterogeneous groups in terms of age, severity and other var-
iables. So far, the only available long-term longitudinal prospectively collected data on 6MWT,
the measure most commonly used as the primary outcome measure in clinical trials, are lim-
ited to the 3-year changes in patients amenable to skip exon 51, using two large national data-
set[3]. Less is known about the 3-year changes in other subgroups of boys with mutations such
as those amenable to skip exons 44, 45 and 53. This information is relevant because there are
current clinical trials specifically targeting these subgroups of mutations and using 6MWT as
the primary measure.
In the present study, we report the 36 months longitudinal natural history data in a cohort
of patients with deletions amenable to skip exons 44, 45, 51, 53. This was possible as the result
of an international effort from tertiary care centers sharing similar standards of care and
training.
The 36 month follow up in our study confirms and expands previous findings using the
North Star Ambulatory Assessment (NSAA) at 24 months [8] reporting that the difference
between subgroups amenable to skip different exons is not significant after 12 months but
becomes significant at 24 months. In our study, using the 6MWD, we confirmed that the dif-
ference was not significant at 12 months but became significant at both 24 (p�0.05) and 36
months (p�0.01).
As anticipated from previous studies [5–8], mutations amenable to skip exon 53 had an
overall lower baseline values and more negative changes than the other subgroups, with nearly
similar results in the subgroup amenable to skip exon 51. At the other end of the spectrum, the
deletions eligible to skip exon 44 had better results both at baseline and on follow up. Deletions
amenable to skip for exon 45 were associated with a more variable pattern of changes.
In line with previous studies in larger cohorts of DMD boys including all types of mutations
[13], patients below and above 7 years had different patterns of progressions with a difference
between the two groups at both 24 and 36 months. In the boys younger than 7 years at baseline
there was an overall mean improvement on the 6MWT over 36 months with some relative
decline only in the third year. The only exception was the subgroup with patients skipping
exon 53 who had an initial mean improvement only in the first year followed by some decline
already in the second year and a more obvious decline in the third year with mean values
below 300 meters at 36 months. It is of note that the 2 patients with earliest loss of ambulation
(age 8 years) were both amenable to skip exon 53.
When we looked at individual mutations, single exon deletions were more often associated
with less drastic changes, but there was no consistent or obvious pattern of changes as some
individual mutations were often associated with variable functional pattern of progression.
These results are consistent with previous observations that single deletions, such as deletion
of exon 44 or deletion of exon 45 were each associated with variable phenotypes ranging from
Becker or intermediate phenotypes to more typical DMD phenotype with loss of ambulation
before the age of 12 years. [16].
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In this paper, we were also interested to establish whether the findings observed in a previ-
ous paper that a combination of 6MWT and TRF could identify also in the individual sub-
groups the clinical pattern for a faster decline[14].
In our cohort 13 of the 21 (62%) with a combination of TRF>6 sec and 6MWT <350 m
lost ambulation within 36 months, irrespective of the genotype. The main difference was that
this combination occurred less frequently and at an older age in the patients amenable to skip
exon 44 compared to the other subgroups.
In conclusion, our international effort provides details of the 3 year 6MWT changes in
patients with deletions amenable to skip different exons, confirming that with increasing dura-
tion of the study the differences between subgroups becomes more obvious. Patients amenable
of skipping exon 53 in particular appear to have earlier onset of decline and a higher risk of
more drastic changes and loss of ambulation. Patients amenable of skipping 45 had a variable
progression.
These findings are compatible with previous observations based on muscle biopsies show-
ing different residual dystrophin expression in these subgroups [16–18]. Other factors such as
modifier genes [19–21] that were not studied in our cohort may also account for the variability
observed.
Further analysis, taking into account type and regime of steroids in the individual sub-
groups or individual mutations, was limited by the small numbers and by the variability in age
and baseline functional status. In each subgroup there was some variability that could not
always be justified by the presence of single deletions, full dose steroids or other variables pre-
viously associated with more favorable outcome. Including other variables, such as weight,
height and body mass index, that were not systematically noted in our cohort, may also help to
define a panel of multiple measures that, as recently shown in other DMD cohorts, may be of
help to establish more accurate trajectories of progression using advanced statistical analysis
[22, 23].
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